Heartflow, Inc.
- HTFL · Nasdaq
- Surgical & Medical Instruments & Apparatus
- San Francisco, CA
- 843 employees
- CIK 0001464521
Updated from SEC filings through
Top things to know
Executives
-
John C.M. Farquhar Chief Executive Officer 4, 2026-09-14 -
Vikram Verghese Chief Financial Officer 4, 2026-09-18 -
Campbell Rogers Chief Medical Officer 4, 2026-09-21 - Marie L. Jones Chief Accounting Officer 4, 2026-08-10
- Mhairi L. Jones Chief Accounting Officer 10-K, 2026-03-18
- Campbell D.K. Rogers, M.D. Chief Medical Officer DEF 14A, 2026-04-29
What leadership is saying
“The second quarter reflects the growing strength of Heartflow's category leadership and unique AI technology platform for identifying, diagnosing, managing and treating coronary artery disease”
Earnings press release (8-K Ex. 99.1), filed August 13, 2026
Heartflow, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in San Francisco, CA. It trades as HTFL on Nasdaq. Revenue was $176M in the fiscal year ending December 31, 2025, +39.9% from the year before. It reported about 843 employees. John C.M. Farquhar is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $176M 10-K, 2026-03-18 | $126M 10-K, 2026-03-18 | $87.2M 10-K, 2026-03-18 |
| Operating income | -$64.1M 10-K, 2026-03-18 | -$61.2M 10-K, 2026-03-18 | -$72.9M 10-K, 2026-03-18 |
| SG&A | $134M 10-K, 2026-03-18 | $112M 10-K, 2026-03-18 | $95.1M 10-K, 2026-03-18 |
| Net income | -$117M 10-K, 2026-03-18 | -$96.4M 10-K, 2026-03-18 | -$95.7M 10-K, 2026-03-18 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| John C.M. Farquhar President and Chief Executive Officer at Heartflow | Chief Executive Officer | 4, 2026-09-14 |
| Vikram Verghese CFO at Heartflow (NASDAQ: HTFL) | Chief Financial Officer | 4, 2026-09-18 |
| Campbell Rogers Executive Vice President and Chief Medical Officer at Heartflow, Inc | Chief Medical Officer | 4, 2026-09-21 |
| Marie L. Jones | Chief Accounting Officer | 4, 2026-08-10 |
| Campbell D.K. Rogers, M.D. | Named in proxy bio: Chief Medical Officer | DEF 14A, 2026-04-29 |
| Mhairi L. Jones | Chief Accounting Officer | 10-K, 2026-03-18 |
| William C. Weldon | Chair of the Board of Directors | 10-K, 2026-03-18 |
| Casey M. Tansey | Director | 10-K, 2026-03-18 |
| Jeffrey C. Lightcap | Director | 10-K, 2026-03-18 |
| Julie A. Cullivan | Director | 10-K, 2026-03-18 |
| Timothy C. Barabe | Director | 10-K, 2026-03-18 |
What Heartflow, Inc. does
We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 87.0 million (as of July 31, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $0 (as of June 30, 2025) | 10-K, March 18, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
| Latest proxy statement | Meeting June 16, 2026 (filed April 29, 2026) | DEF 14A, April 29, 2026 |
| Auditor | PricewaterhouseCoopers LLP (San Jose, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 22, 2026 | Campbell Rogers Chief Medical Officer | Sale | 23,933 | $1.3M | Form 4, October 26, 2026 |
| October 12, 2026 | John C.M. Farquhar Chief Executive Officer | Sale | 38,900 | $1.9M | Form 4, October 14, 2026 |
| September 18, 2026 | Campbell Rogers Chief Medical Officer | Sale | 19,682 | $987K | Form 4, September 21, 2026 |
| September 18, 2026 | Vikram Verghese Chief Financial Officer | Sale | 24,345 | $1.2M | Form 4, September 18, 2026 |
| September 15, 2026 | Vikram Verghese Chief Financial Officer | Sale | 34,975 | $1.8M | Form 4, September 15, 2026 |
| September 11, 2026 | John C.M. Farquhar Chief Executive Officer | Sale | 38,900 | $1.8M | Form 4, September 14, 2026 |
| September 8, 2026 | Vikram Verghese Chief Financial Officer | Sale | 6,640 | $332K | Form 4, September 10, 2026 |
| September 3, 2026 | Vikram Verghese Chief Financial Officer | Sale | 33,416 | $1.7M | Form 4, September 4, 2026 |
Recent 8-K events
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-18
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-18
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-10
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-08-25
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2025-08-11
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
Frequently asked questions about Heartflow, Inc.
- What does Heartflow, Inc. do?
- In its own words, from Item 1 of its 10-K: "We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD."
- What is Heartflow, Inc.'s revenue?
- $176M for the fiscal year ending December 31, 2025, from its 10-K filed March 18, 2026.
- Is Heartflow, Inc. profitable?
- Heartflow, Inc. reported net income of -$117M for the fiscal year ending December 31, 2025.
- How many employees does Heartflow, Inc. have?
- About 843 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Heartflow, Inc.?
- John C.M. Farquhar, Chief Executive Officer, as named in a 4 filed September 14, 2026.
- Who is the CFO of Heartflow, Inc.?
- Vikram Verghese, Chief Financial Officer, as named in a 4 filed September 18, 2026.
- Where is Heartflow, Inc. headquartered?
- San Francisco, CA.
- What is Heartflow, Inc.'s stock ticker?
- HTFL on Nasdaq.
- What industry is Heartflow, Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Heartflow, Inc.'s website?
- heartflow.com.
- When does Heartflow, Inc. report earnings next?
- November 12, 2026 at 16:30. Source: pg_future_events.
- Is Heartflow, Inc. a public company?
- Yes. Heartflow, Inc. files with the SEC under CIK 0001464521 and trades as HTFL.
- Who audits Heartflow, Inc.?
- PricewaterhouseCoopers LLP, San Jose, California, as named in its latest annual report (10-K).
- How many shares of Heartflow, Inc. are outstanding?
- 87.0 million shares as of July 31, 2026, from its 10-Q filed August 13, 2026.
- What is Heartflow, Inc.'s public float?
- $0 as of June 30, 2025, as reported on the cover of its 10-K filed March 18, 2026.
- How many business segments does Heartflow, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- When is Heartflow, Inc.'s annual shareholder meeting?
- June 16, 2026, per its proxy statement (DEF 14A) filed April 29, 2026.
- Have Heartflow, Inc. insiders traded stock recently?
- Since December 16, 2025, officers and directors reported 28 open-market sales worth about $26.3M and 1 purchase worth about $1.1M on Forms 4 and 5. The most recent: Campbell Rogers (Chief Medical Officer) sold 23,933 shares on October 22, 2026.